Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
BMJ Publishing Group
2022
|